Custom Antibody Discovery & Development Services
From Antigen Design to Lead Candidate
Biomolecular Discovery Services (BDS) provides comprehensive antibody discovery platforms designed to overcome the limitations of traditional immunization. Whether you are targeting complex membrane proteins, seeking high-stability VHH single-domain antibodies, or require rapid affinity maturation, we tailor the discovery strategy to your therapeutic or diagnostic goals.
Don't settle for weak binders. Discover antibodies with high specificity and strong developability.
Discuss Your Target With a Scientist
A Multi-Platform Approach to Discovery
We do not believe in a one-size-fits-all approach. Successful discovery requires selecting the right library and screening method for your specific antigen. BDS offers industry-leading capabilities in both standard IgG and single-domain formats.
Phage Display Discovery
Our core expertise. We utilize proprietary phage display libraries to screen billions of antibody variants against your target. This in vitro method allows for precise control over selection conditions, enabling the isolation of binders against toxic, non-immunogenic, or highly conserved antigens.
Best for: Difficult targets, rapid screening, and human antibody discovery.
Explore Phage Display Services →
VHH (Single Domain) Libraries
Leverage the stability and tissue-penetration power of camelid antibodies. We offer access to diverse VHH libraries (naive and synthetic) ideal for therapeutic development, CAR-T applications, and diagnostic reagents.
Best for: Tissue penetration, bispecific engineering, and high-stability applications.
Explore VHH & Synthetic Libraries →
Antibody Optimization & Engineering
Discovery is just the first step. We optimize lead candidates to improve binding affinity, stability, and manufacturability. Our affinity maturation services can increase binding strength by 10–1000 fold without losing specificity.
Best for: Improving lead candidates, engineering, and humanization.
View Affinity Maturation Services →
Why Choose BDS for Discovery?
We Specialize in "Difficult" Targets
Standard hybridoma methods often fail against GPCRs, ion channels, and other transmembrane proteins. Our in vitro display technologies allow us to present antigens in more native-like conformations, helping ensure that discovered antibodies bind to biologically relevant epitopes instead of artifacts.
Next-Generation Sequencing (NGS) Integration
We don't just pick the first binder we see. By coupling phage display with NGS and advanced bioinformatics, we analyze the entire enrichment landscape. This allows us to identify rare, high-affinity clones that traditional Sanger sequencing would miss and to better understand sequence families, liability profiles, and developability risks early in the program.
Seamless Transition to Production
Once a lead is identified, we handle downstream expression and purification. From micro-scale production for initial assays to pilot batches for validation, BDS keeps your project under one roof to reduce handoff risk and accelerate timelines.
View Antibody Production Services →
Our Discovery Workflow
Every program is customized, but our antibody discovery workflow typically includes:
- Antigen Strategy: We consult with you to determine the best antigen format (soluble protein, peptide, or cell-based) to expose the desired epitope.
- Library Selection: We select the appropriate naive, immune, or synthetic library based on the target species and desired antibody format (scFv, Fab, VHH).
- Panning & Screening: Multiple rounds of biopanning are performed, with increasing stringency to enrich for high-affinity, target-specific binders.
- Characterization: Positive clones are sequenced, expressed, and validated via ELISA, flow cytometry, or other assay formats aligned with your end application.
- Delivery: You receive purified antibodies, sequence data, and a full project report summarizing strategy, selections, and results.
Ready to Start Your Discovery Project?
Accelerate your research with a partner who understands the science of selection. Whether you are at hit-finding, optimization, or ready to transition to production, BDS can support your antibody discovery and development program.
